Research & Innovation
Women in Science
Education and career development
CNIO and Society
About the CNIO
What is it we do
Thanks to our friends donations
Other contributions: CNIO Arte
CNIO Friends Newsletter
CNIO-”la Caixa” Foundation Frontiers Meetings
Women in Science Office Seminar
Activities & Events
Facts & Figures
CNIO Euality Plan
Contacts & Suggestions
Links of Interest
Career Development Programmes
How to Find Us
CNIO Open doors
CNIO & The City
CNIO Friends welcomes Víctor Frankenstein
CNIO Friends Newsletter
Outreach to Society
Potential drugs originated at CNIO to be developed by AUM Biosciences in Asia
A group of multi-target anti-tumour compounds, the IBL-300 series, discovered at the Spanish...
EMBO Molecular Medicine.
CNIO researchers find effective drug combinations for glioblastoma in mice
Usually, scientists study the molecular biology of cancer to find new treatments, but sometimes, it...
CNIO researchers discover a new way to protect against high-dose radiation damage
Radiotherapy, a common treatment for cancer, is one of the most effective ways to destroy cancer...
Journal of Experimental Medicine.
CNIO researchers assess melanoma progression with a new liquid biopsy technique
When the surgeon surgically removes a melanoma, some patients are said to be ‘cancer-free’ and...
CNIO researchers succeed at removing some types of pancreatic cancer in animal models
Researchers from the Experimental Oncology Group, led by Mariano Barbacid at the Spanish National...
The American Journal of Human Genetics.
CNIO researchers identify a new gene involved in the development of a rare endocrine tumour
Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours: there are only 3-8 cases...
The New England Journal of Medicine (NEJM).
An international clinical trial extends the effectiveness of immunotherapy to more lung cancer patients
The strategy for triggering the patient’s own immune system to attack cancer, immunotherapy, is...
A new methodology predicts the risk of relapse in patients with acute myeloid leukemia
The acute myeloid leukemia (AML) is the most common haematological cancer in adults. With a 5-year...
First blood-based biomarker in response to the treatment of the most aggressive prostate cancer
In collaboration with British and Italian researchers
Política de privacidad